Orient Pharma Co., Ltd. (TPEX:4166)

Market Cap	5.71B
Revenue (ttm)	1.26B
Net Income (ttm)	79.71M
Shares Out	223.04M
EPS (ttm)	0.36
PE Ratio	71.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	122,201
Average Volume	278,957
Open	25.80
Previous Close	25.80
Day's Range	25.55 - 25.80
52-Week Range	22.30 - 50.70
Beta	-0.01
RSI	42.45
Earnings Date	Nov 28, 2025

About Orient Pharma

Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson’s and Alzheimer’s diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 173
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4166

Financial Performance

In 2024, Orient Pharma's revenue was 1.22 billion, an increase of 37.41% compared to the previous year's 889.91 million. Earnings were 107.37 million, an increase of 381.76%.